(Meloxicam + rizatriptan) is under clinical development by Axsome Therapeutics and currently in Pre-Registration for Migraine. According to GlobalData, Pre-Registration drugs for Migraine have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how (Meloxicam + rizatriptan)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Meloxicam + rizatriptan) overview
AXS-07 is under development for the treatment of acute migraine. It is a fixed dose combination of meloxicam (new molecular entity) and rizatriptan. The drug candidate is administered through oral route. Meloxicam acts by targeting prostaglandin G/H synthase 2 and rizatriptan acts by targeting 5-hydroxytryptamine receptor 1B. It is being developed based on MoSEIC (molecular solubility enhanced inclusion complex) technology.
Axsome Therapeutics overview
Axsome Therapeutics (Axsome) is a biopharmaceutical company that develops and commercializes therapies for the treatment of central nervous system (CNS) disorders. The company’s pipeline products include AXS-05, for the treatment of resistant depression, smoking cessation and agitation in Alzheimer’s disease, AXS-07-migraine, AXS-12-narcolepsy, and AXS-14, for the treatment of fibromyalgia. Its other products include sunosi and auvelity. The company supplies its products through internal sales, distributors and an internal marketing group in the US and outside the US. Axsome is headquartered in New York, the US.
For a complete picture of (Meloxicam + rizatriptan)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
